Alzamend Neuro, Inc. Common Stock (ALZN) Stock Price, Quote & AI Analysis

Live ALZN stock price, real-time charts, AI-powered trade signals, technical analysis, earnings insights, and market sentiment for Alzamend Neuro, Inc. Common Stock.

TradeVae provides AI-driven analysis and real-time market intelligence for Alzamend Neuro, Inc. Common Stock (ALZN), including price action, technical indicators, earnings performance, analyst sentiment, and short-term trade setups.

ALZN
Alzamend Neuro, Inc. Common Stock
real-time
$0.00 +0.00 (+0.00%)
Open
2.000000
High
2.050000
Low
1.940000
Volume
47,022
VWAP
-
Market Cap
$7,489,159.88
52W Range
$1.58 - $10.17
P/E Ratio
-
EPS
-
Debt/Equity
-
EV/EBITDA
-
Upcoming Earnings
Mar 9, 2026 Q3
Market
EPS Estimate: $-1.9635
Loading chart...

AI Analysis

Explore comprehensive AI-powered analysis including summary insights, bull and bear cases, key risks, and factors to watch.

Loading...

Generating AI analysis...

-
-
-
-

Alzamend Neuro, Inc. Common Stock's fundamentals reflect its scale, profitability, and position within the global technology sector. Key valuation and financial metrics are summarized below, followed by detailed financial statements.

Alzamend Neuro, Inc. Common Stock Overview

Company information

Company Overview

Alzamend Neuro, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which is in Phase II clinical trial, and delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bipolar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders, and AL002, which completed preclinical stage, and uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. The company was founded on February 26, 2016 by Milton C. Ault, III and is headquartered in Atlanta, GA.

Company Details
Market Cap
$7.45M
Shares Outstanding
3,801,604
Weighted Shares Outstanding
3,801,604
CEO
Stephan Jackman
Address
3500 LENOX RD. NE, ATLANTA, GA, 30326
Employees
7
Industry
PHARMACEUTICAL PREPARATIONS
Exchange
XNAS

Technical Indicators

Key technical analysis metrics and signals

Loading...

Loading technical indicators...

Valuation Metrics

Key valuation ratios and comparisons

Loading...

Loading valuation metrics...

Alzamend Neuro, Inc. Common Stock Earnings & Financial Statements

Earnings Calendar

Upcoming earnings dates and historical surprises

Loading...

Loading earnings calendar...

Financial Statements

Income statements, balance sheets, and cash flow

Loading...

Loading income statements...

Loading...

Loading balance sheets...

Loading...

Loading cash flow statements...